仑伐替尼联合帕博利珠单抗对比仑伐替尼联合安慰剂治疗晚期肝细胞癌(LEAP-002):一项随机、双盲、3期试验
LEAP-002研究在全球172个中心随机分配794例不可切除肝细胞癌患者,接受仑伐替尼联合帕博利珠单抗或仑伐替尼联合安慰剂一线治疗。最终分析显示,联合组中位总生存期21.2个月对比安慰剂组19.0个月(HR 0.84,95%CI 0.71-1.00,分层log-rank P=0.023),未达到预设优效界值(单侧P=0.019);中位无进展生存期8.2个月对比8.0个月(HR 0.87,95%CI 0.73-1.02,分层log-rank P=0.047),亦未达到预设优效界值(单侧P=0.002)。
要点
- 联合组中位总生存期21.2个月对比安慰剂组19.0个月,HR 0.84,未达到预设优效界值。
- 联合组中位无进展生存期8.2个月对比安慰剂组8.0个月,HR 0.87,未达到预设优效界值。
- 常见治疗相关3-4级不良事件为高血压、天冬氨酸氨基转移酶升高和腹泻。
核心结论
- 仑伐替尼联合帕博利珠单抗对比仑伐替尼联合安慰剂未能达到改善总生存期和无进展生存期的预设显著性,研究结果不支持改变临床实践。
研究设计与样本
- 全球、随机、双盲、3期研究(LEAP-002),在172个全球中心入组年龄18岁及以上、不可切除肝细胞癌、Child-Pugh A级肝病、ECOG体能状态0或1、无既往系统治疗的患者。
- 患者按1:1随机分配至仑伐替尼(体重<60 kg,8 mg/日;体重≥60 kg,12 mg/日)联合帕博利珠单抗(200 mg每3周)组或仑伐替尼联合安慰剂组,随机化按地理区域、大血管门静脉侵犯或肝外转移或两者兼有、甲胎蛋白浓度和ECOG体能状态分层。
- 双主要终点为意向治疗人群的总生存期(最终总生存分析优效性界值单侧P=0.019,最终分析在532个事件后发生)和无进展生存期(优效性界值单侧P=0.002,最终分析在571个事件后发生),报告最终分析结果。
主要发现
- 2019年1月17日至2020年4月28日,评估1309例患者,794例随机分配至仑伐替尼联合帕博利珠单抗组(n=395)或仑伐替尼联合安慰剂组(n=399)。
- 中位年龄66.0岁(IQR 57.0-72.0),794例中男性644例(81%)、女性150例(19%);亚洲人345例(43%)、白人345例(43%)、多种族22例(3%)、美洲印第安人或阿拉斯加原住民21例(3%)、夏威夷原住民或其他太平洋岛民21例(3%)、黑人或非裔美国人13例(2%)、种族数据缺失46例(6%)。
- 截至最终分析数据截止日期(2022年6月21日)中位随访32.1个月(IQR 29.4-35.3)。
- 联合组中位总生存期21.2个月(95%CI 19.0-23.6;395例中252例[64%]死亡)对比安慰剂组19.0个月(95%CI 17.2-21.7;399例中282例[71%]死亡),HR 0.84(95%CI 0.71-1.00;分层log-rank P=0.023)。
- 截至无进展生存期最终分析数据截止日期(2021年4月5日),联合组中位无进展生存期8.2个月(95%CI 6.4-8.4;发生270个事件[42例死亡;228例进展])对比安慰剂组8.0个月(95%CI 6.3-8.2;发生301个事件[36例死亡;265例进展]),HR 0.87(95%CI 0.73-1.02;分层log-rank P=0.047)。
关键数值与推荐
- 总生存期优效性界值为最终总生存分析单侧P=0.019,实际分层log-rank P=0.023,未达到预设显著性。
- 无进展生存期优效性界值为单侧P=0.002,实际分层log-rank P=0.047,未达到预设显著性。
- 最常见的治疗相关3-4级不良事件为高血压(联合组69例[17%]对比安慰剂组68例[17%])、天冬氨酸氨基转移酶升高(27例[7%]对比17例[4%])和腹泻(25例[6%]对比15例[4%])。
- 治疗相关死亡:联合组4例(1%)(胃肠道出血和肝肾综合征各1例,肝性脑病2例),安慰剂组3例(1%)(胃肠道出血、肝肾综合征和脑血管意外各1例)。
临床怎么用
- 研究结果不支持改变临床实践。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Systemic therapies have improved the management of hepatocellular carcinoma, but there is still a need to further enhance overall survival in first-line advanced stages. This study aimed to evaluate the addition of pembrolizumab to lenvatinib versus lenvatinib plus placebo in the first-line setting for unresectable hepatocellular carcinoma. METHODS: In this global, randomised, double-blind, phase 3 study (LEAP-002), patients aged 18 years or older with unresectable hepatocellular carcinoma, Child Pugh class A liver disease, an Eastern Cooperative Oncology Group performance status of 0 or 1, and no previous systemic treatment were enrolled at 172 global sites. Patients were randomly assigned (1:1) with a central interactive voice-response system (block size of 4) to receive lenvatinib (bodyweight <60 kg, 8 mg/day; bodyweight ≥60 kg, 12 mg/day) plus pembrolizumab (200 mg every 3 weeks) or lenvatinib plus placebo. Randomisation was stratified by geographical region, macrovascular portal vein invasion or extrahepatic spread or both, α-fetoprotein concentration, and Eastern Cooperative Oncology Group performance status. Dual primary endpoints were overall survival (superiority threshold at final overall survival analysis, one-sided p=0·019; final analysis to occur after 532 events) and progression-free survival (superiority threshold one-sided p=0·002; final analysis to occur after 571 events) in the intention-to-treat population. Results from the final analysis are reported. This study is registered with ClinicalTrials.gov, NCT03713593, and is active but not recruiting. FINDINGS: Between Jan 17, 2019, and April 28, 2020, of 1309 patients assessed, 794 were randomly assigned to lenvatinib plus pembrolizumab (n=395) or lenvatinib plus placebo (n=399). Median age was 66·0 years (IQR 57·0-72·0), 644 (81%) of 794 were male, 150 (19%) were female, 345 (43%) were Asian, 345 (43%) were White, 22 (3%) were multiple races, 21 (3%) were American Indian or Alaska Native, 21 (3%) were Native Hawaiian or other Pacific Islander, 13 (2%) were Black or African American, and 46 (6%) did not have available race data. Median follow up as of data cutoff for the final analysis (June 21, 2022) was 32·1 months (IQR 29·4-35·3). Median overall survival was 21·2 months (95% CI 19·0-23·6; 252 [64%] of 395 died) with lenvatinib plus pembrolizumab versus 19·0 months (17·2-21·7; 282 [71%] of 399 died) with lenvatinib plus placebo (hazard ratio [HR] 0·84; 95% CI 0·71-1·00; stratified log-rank p=0·023). As of data cutoff for the progression-free survival final analysis (April 5, 2021), median progression-free survival was 8·2 months (95% CI 6·4-8·4; 270 events occurred [42 deaths; 228 progressions]) with lenvatinib plus pembrolizumab versus 8·0 months (6·3-8·2; 301 events occurred [36 deaths; 265 progressions]) with lenvatinib plus placebo (HR 0·87; 95% CI 0·73-1·02; stratified log-rank p=0·047). The most common treatment-related grade 3-4 adverse events were hypertension (69 [17%] of 395 patients in the lenvatinib plus pembrolizumab group vs 68 [17%] of 395 patients) in the lenvatinib plus placebo group), increased aspartate aminotransferase (27 [7%] vs 17 [4%]), and diarrhoea (25 [6%] vs 15 [4%]). Treatment-related deaths occurred in four (1%) patients in the lenvatinib plus pembrolizumab group (due to gastrointestinal haemorrhage and hepatorenal syndrome [n=1 each] and hepatic encephalopathy [n=2]) and in three (1%) patients in the lenvatinib plus placebo group (due to gastrointestinal haemorrhage, hepatorenal syndrome, and cerebrovascular accident [n=1 each]). INTERPRETATION: In earlier studies, the addition of pembrolizumab to lenvatinib as first-line therapy for advanced hepatocellular carcinoma has shown promising clinical activity; however, lenvatinib plus pembrolizumab did not meet prespecified significance for improved overall survival and progression-free survival versus lenvatinib plus placebo. Our findings do not support a change in clinical practice. FUNDING: Eisai US, and Merck Sharp & Dohme, a subsidiary of Merck.
引用
- Llovet JM, Kudo M, Merle P, et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023. PMID: 38039993. doi:10.1016/S1470-2045(23)00469-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。